<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939211</url>
  </required_header>
  <id_info>
    <org_study_id>D1882C00003</org_study_id>
    <nct_id>NCT00939211</nct_id>
  </id_info>
  <brief_title>The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>LaCrossE</acronym>
  <official_title>A Double-blind, Double-dummy, Placebo-controlled, Randomised, Multi-centre, 5-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of Inhaled AZD9164 Compared to Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition with
      deteriorating lung function over the years. Patients with COPD experience symptoms of
      shortness of breath, cough and sputum production. This study is to assess the treatment
      effects after inhalation of three different single doses of AZD9164 (100, 400 and 1200 mcg)
      and one single dose of tiotropium (18 mcg). One dose of placebo will be given as comparator.
      25 patients are to participate in the study and all will be recruited in Sweden. Each patient
      will visit the study doctor 9 times during the study, whereof 5 visits will be overnight
      visits. All examinations, treatment and the follow-up is free of charge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose</measure>
    <time_frame>0, 15 min, 30 min, 60 min, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
    <description>Maximum FEV1 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose</measure>
    <time_frame>22 h, 24 h, 26 h</time_frame>
    <description>Trough FEV1 value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 0 - 24 Hours Post Dose</measure>
    <time_frame>0, 15 min, 30 min, 60 min, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
    <description>Average FEV1 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1), Effect at 15 Minutes Post-dose</measure>
    <time_frame>15 min</time_frame>
    <description>15 min FEV1 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average systolic blood pressure value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average diastolic blood pressure value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average pulse value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average heart rate value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF, Average Effect Over 0 - 4 Hours Post-dose</measure>
    <time_frame>0, 30 min, 2 h, 4 h</time_frame>
    <description>Average QTcF value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD9164 Cmax</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
    <description>Maximum plasma concentration of AZD9164</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD9164 AUC0-24</measure>
    <time_frame>0, 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
    <description>Area under the AZD9164 plasma concentration curve</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>AZD9164 100 mcg First, then Placebo for Spririva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9164 400 mcg First, then Placebo for Spiriva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9164 1200 mcg First, then Placebo for Spiriva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva 18 mcg First, then Placebo for AZD9164</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Spiriva First, then Placebo for AZD9164</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9164</intervention_name>
    <description>Solution for inhalation through nebulization, single dose</description>
    <arm_group_label>AZD9164 100 mcg First, then Placebo for Spririva</arm_group_label>
    <arm_group_label>AZD9164 400 mcg First, then Placebo for Spiriva</arm_group_label>
    <arm_group_label>AZD9164 1200 mcg First, then Placebo for Spiriva</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>Spiriva 18 mcg First, then Placebo for AZD9164</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>AZD9164 100 mcg First, then Placebo for Spririva</arm_group_label>
    <arm_group_label>AZD9164 400 mcg First, then Placebo for Spiriva</arm_group_label>
    <arm_group_label>AZD9164 1200 mcg First, then Placebo for Spiriva</arm_group_label>
    <arm_group_label>Spiriva 18 mcg First, then Placebo for AZD9164</arm_group_label>
    <arm_group_label>Placebo for Spiriva First, then Placebo for AZD9164</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of COPD

          -  FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post-
             bronchodilator FEV1/FVC &lt; 70%

        Exclusion Criteria:

          -  Any clinically relevant abnormal findings at screening examinations

          -  Any clinically significant disease or disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leif Bjermer, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital in Lund, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <results_first_submitted>July 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2011</results_first_posted>
  <last_update_submitted>July 8, 2011</last_update_submitted>
  <last_update_submitted_qc>July 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carin Jorup, MD/MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>inhalation</keyword>
  <keyword>long-acting muscarinic receptor antagonist (LAMA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study has been performed at four centers in Sweden. The first subject entered the study on 23 June 2009 and the last subject completed the study on 6 November 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>AZD9164 100 Mcg First, Then Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28">Cross-over study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>AZD9164 400 Mcg First, Then Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>AZD9164 1200 Mcg First, Then Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Spiriva 18 Mcg First, Then Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Number of Baseline Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" lower_limit="51" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose</title>
        <description>Maximum FEV1 value</description>
        <time_frame>0, 15 min, 30 min, 60 min, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose</title>
          <description>Maximum FEV1 value</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.36"/>
                    <measurement group_id="O2" value="1.79" spread="0.39"/>
                    <measurement group_id="O3" value="1.72" spread="0.39"/>
                    <measurement group_id="O4" value="1.71" spread="0.35"/>
                    <measurement group_id="O5" value="1.63" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose</title>
        <description>Trough FEV1 value</description>
        <time_frame>22 h, 24 h, 26 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose</title>
          <description>Trough FEV1 value</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.38"/>
                    <measurement group_id="O2" value="1.63" spread="0.38"/>
                    <measurement group_id="O3" value="1.62" spread="0.38"/>
                    <measurement group_id="O4" value="1.57" spread="0.35"/>
                    <measurement group_id="O5" value="1.52" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 0 - 24 Hours Post Dose</title>
        <description>Average FEV1 value</description>
        <time_frame>0, 15 min, 30 min, 60 min, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 18 h, 22 h, 24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Average Effect Over 0 - 24 Hours Post Dose</title>
          <description>Average FEV1 value</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.36"/>
                    <measurement group_id="O2" value="1.63" spread="0.39"/>
                    <measurement group_id="O3" value="1.56" spread="0.38"/>
                    <measurement group_id="O4" value="1.58" spread="0.35"/>
                    <measurement group_id="O5" value="1.50" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1), Effect at 15 Minutes Post-dose</title>
        <description>15 min FEV1 value</description>
        <time_frame>15 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1), Effect at 15 Minutes Post-dose</title>
          <description>15 min FEV1 value</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.38"/>
                    <measurement group_id="O2" value="1.30" spread="0.42"/>
                    <measurement group_id="O3" value="1.25" spread="0.44"/>
                    <measurement group_id="O4" value="1.55" spread="0.36"/>
                    <measurement group_id="O5" value="1.49" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average systolic blood pressure value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average systolic blood pressure value</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.5" spread="15.6"/>
                    <measurement group_id="O2" value="127.9" spread="14.8"/>
                    <measurement group_id="O3" value="127.3" spread="14.9"/>
                    <measurement group_id="O4" value="128.0" spread="13.3"/>
                    <measurement group_id="O5" value="126.5" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average diastolic blood pressure value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average diastolic blood pressure value</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="7.9"/>
                    <measurement group_id="O2" value="75.6" spread="8.2"/>
                    <measurement group_id="O3" value="74.2" spread="6.7"/>
                    <measurement group_id="O4" value="74.8" spread="6.2"/>
                    <measurement group_id="O5" value="73.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average pulse value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average pulse value</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" spread="7.6"/>
                    <measurement group_id="O2" value="62.9" spread="7.1"/>
                    <measurement group_id="O3" value="64.8" spread="8.0"/>
                    <measurement group_id="O4" value="60.2" spread="7.6"/>
                    <measurement group_id="O5" value="61.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average heart rate value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average heart rate value</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="6.9"/>
                    <measurement group_id="O2" value="62.8" spread="7.8"/>
                    <measurement group_id="O3" value="65.2" spread="7.4"/>
                    <measurement group_id="O4" value="61.1" spread="7.4"/>
                    <measurement group_id="O5" value="61.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF, Average Effect Over 0 - 4 Hours Post-dose</title>
        <description>Average QTcF value</description>
        <time_frame>0, 30 min, 2 h, 4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF, Average Effect Over 0 - 4 Hours Post-dose</title>
          <description>Average QTcF value</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400" spread="23.1"/>
                    <measurement group_id="O2" value="399" spread="25.8"/>
                    <measurement group_id="O3" value="396" spread="25.0"/>
                    <measurement group_id="O4" value="401" spread="26.8"/>
                    <measurement group_id="O5" value="398" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD9164 Cmax</title>
        <description>Maximum plasma concentration of AZD9164</description>
        <time_frame>0, 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD9164 Cmax</title>
          <description>Maximum plasma concentration of AZD9164</description>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.529" lower_limit="0.24" upper_limit="1.55"/>
                    <measurement group_id="O2" value="3.629" lower_limit="1.31" upper_limit="13.9"/>
                    <measurement group_id="O3" value="20.02" lower_limit="6.15" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD9164 AUC0-24</title>
        <description>Area under the AZD9164 plasma concentration curve</description>
        <time_frame>0, 5 min, 15 min, 30 min, 60 min, 90 min, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O2">
            <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O3">
            <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
            <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
            <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
          <group group_id="O5">
            <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
            <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD9164 AUC0-24</title>
          <description>Area under the AZD9164 plasma concentration curve</description>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" lower_limit="1.2" upper_limit="16.2"/>
                    <measurement group_id="O2" value="15.2" lower_limit="6.9" upper_limit="66.8"/>
                    <measurement group_id="O3" value="58.1" lower_limit="21.8" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD9164 100 Mcg First, Then Placebo for Spiriva</title>
          <description>1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
        </group>
        <group group_id="E2">
          <title>AZD9164 400 Mcg First, Then Placebo for Spiriva</title>
          <description>1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
        </group>
        <group group_id="E3">
          <title>AZD9164 1200 Mcg First, Then Placebo for Spiriva</title>
          <description>1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation</description>
        </group>
        <group group_id="E4">
          <title>Spiriva 18 Mcg First, Then Placebo for AZD9164</title>
          <description>1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)</description>
        </group>
        <group group_id="E5">
          <title>Placebo for Spiriva First, Then Placebo for AZD9164</title>
          <description>1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+441509645895</phone>
      <email>clinicaltrialtransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

